SynthesisJournal of general internal medicine2026
The Correlation Between Serum Uric Acid and Metabolic Dysfunction-Associated Fatty Liver Disease: An Updated Systematic Review and Meta-Analysis.
Synthesis in Journal of general internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveRecent epidemiological evidence suggests that serum uric acid (SUA) levels are believed to be strongly associated with the onset and development of metabolic dysfunction-associated fatty liver disease (MAFLD). Although existing meta-analyses have explored the relationship between the two, new research data continue to emerge, and it is necessary to conduct updated meta-analyses to provide more comprehensive evidence.
methodsFrom the inception of the database until March 2025, we performed an extensive search for pertinent observational studies within the PubMed, Embase, and Web of Science databases. To evaluate the association between SUA levels and MAFLD, random effects models were employed to calculate pooled odds ratios (ORs) and 95% confidence intervals (CIs). Publication bias was assessed using Egger's test.
resultsIn total, 61 studies were analyzed, encompassing 2,151,925 participants. MAFLD prevalence in individuals with hyperuricemia was 59% (between 50 and 69%), with an incidence rate of 28% (between 17 and 47%). Participants exhibiting elevated SUA levels demonstrated a pooled OR of 1.90(95%CI:1.77-2.04) for MAFLD in comparison to those with lower SUA levels. Subgroup analyses further revealed a consistent positive association between SUA levels and MAFLD across various categories, including study design, study quality, sample size, publication year, and geographic location.
conclusionThis meta-analysis further confirmed the positive correlation between high SUA levels and the risk of MAFLD, suggesting that SUA may be a potential biomarker and therapeutic target for MAFLD. REGISTRATION NUMBER: PROSPERO-CRD42024568760.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.